Literature DB >> 30721448

Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7.

Verónica M Borgonio-Cuadra1, Claudia Valdez-Vargas1,2, Sandra Romero-Córdoba3,4, Alfredo Hidalgo-Miranda3, Yessica Tapia-Guerrero1, César M Cerecedo-Zapata5, Oscar Hernández-Hernández1, Bulmaro Cisneros6, Jonathan J Magaña7.   

Abstract

Spinocerebellar ataxia type 7 (SCA7), a neurodegenerative disease characterized by cerebellar ataxia and retinal degeneration, is caused by a CAG repeat expansion in the ATXN7 gene coding region. Disease onset and progression are highly variable between patients, thus identification of specific/sensitive biomarkers that can improve the monitoring of disease progression is an immediate need. Because altered expression of circulating microRNAs (miRNAs) has been shown in various neurological diseases, they could be useful biomarkers for SCA7. In this study, we showed, to our knowledge for the first time, the expression profile of circulating miRNAs in SCA7. Using the TaqMan profiling low density array (TLDA), we found 71 differentially expressed miRNAs in the plasma of SCA7 patients, compared with healthy controls. The reliability of TLDA data was validated independently by quantitative real-time polymerase chain reaction in an independent cohort of patients and controls. We identified four validated miRNAs that possesses the diagnostic value to discriminate between healthy controls and patients (hsa-let-7a-5p, hsa-let7e-5p, hsa-miR-18a-5p, and hsa-miR-30b-5p). The target genes of these four miRNAs were significantly enriched in cellular processes that are relevant to central nervous system function, including Fas-mediated cell-death, heparansulfate biosynthesis, and soluble-N-ethylmaleimide-sensitive factor activating protein receptor pathways. Finally, we identify a signature of four miRNAs associated with disease severity that discriminate between early onset and adult onset, highlighting their potential utility to surveillance disease progression. In summary, circulating miRNAs might provide accessible biomarkers for disease stage and progression and help to identify novel cellular processes involved in SCA7.

Entities:  

Keywords:  Plasma biomarker; PolyQ disease; Spinocerebellar ataxia type 7; miRNAs

Mesh:

Substances:

Year:  2019        PMID: 30721448     DOI: 10.1007/s12035-019-1480-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  79 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype.

Authors:  B P van de Warrenburg; C W Frenken; M G Ausems; T Kleefstra; R J Sinke; N V Knoers; H P Kremer
Journal:  J Neurol       Date:  2001-10       Impact factor: 4.849

3.  Diagnosis of five spinocerebellar ataxia disorders by multiplex amplification and capillary electrophoresis.

Authors:  Michael O Dorschner; Deborah Barden; Karen Stephens
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

4.  Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration.

Authors:  Vikas B Palhan; Shiming Chen; Guang-Hua Peng; Agneta Tjernberg; Armin M Gamper; Yuxin Fan; Brian T Chait; Albert R La Spada; Robert G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

Review 5.  SNAREs and traffic.

Authors:  Wanjin Hong
Journal:  Biochim Biophys Acta       Date:  2005-07-10

6.  SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity.

Authors:  Seung Yun Yoo; Mark E Pennesi; Edwin J Weeber; Bisong Xu; Richard Atkinson; Shiming Chen; Dawna L Armstrong; Samuel M Wu; J David Sweatt; Huda Y Zoghbi
Journal:  Neuron       Date:  2003-02-06       Impact factor: 17.173

7.  Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes.

Authors:  Dominique Helmlinger; Sara Hardy; Souphatta Sasorith; Fabrice Klein; Flavie Robert; Chantal Weber; Laurent Miguet; Noëlle Potier; Alain Van-Dorsselaer; Jean-Marie Wurtz; Jean-Louis Mandel; Làszlò Tora; Didier Devys
Journal:  Hum Mol Genet       Date:  2004-04-28       Impact factor: 6.150

Review 8.  Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses.

Authors:  Chulhee Choi; Etty N Benveniste
Journal:  Brain Res Brain Res Rev       Date:  2004-01

Review 9.  Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy.

Authors:  A Michalik; J-J Martin; C Van Broeckhoven
Journal:  Eur J Hum Genet       Date:  2004-01       Impact factor: 4.246

10.  Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death.

Authors:  Joseph H Su; Aileen J Anderson; David H Cribbs; Christina Tu; Liqi Tong; Patrick Kesslack; Carl W Cotman
Journal:  Neurobiol Dis       Date:  2003-04       Impact factor: 5.996

View more
  3 in total

Review 1.  Founder Effects of Spinocerebellar Ataxias in the American Continents and the Caribbean.

Authors:  Roberto Rodríguez-Labrada; Ana Carolina Martins; Jonathan J Magaña; Yaimeé Vazquez-Mojena; Jacqueline Medrano-Montero; Juan Fernandez-Ruíz; Bulmaro Cisneros; Helio Teive; Karen N McFarland; Maria Luiza Saraiva-Pereira; César M Cerecedo-Zapata; Christopher M Gomez; Tetsuo Ashizawa; Luis Velázquez-Pérez; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2020-06       Impact factor: 3.847

Review 2.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

Review 3.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.